Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
REZILIENT4 trial: what clinicians have said so far
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
- NCT07128199 ↗
- Recruiting
- Taiho Oncology, Inc.
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on REZILIENT4 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on REZILIENT4 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 4 posts on X, typically up to 18 once built |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Versus Placebo in Early Stage NSCLC Patients With Uncommon EGFR Mutations Following Complete Tumor Resection (REZILIENT4)
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Lung Cancer; Adjuvant; Post-surgical; EGFR; Exon 20; Early Stage Lung Cancer; Uncommon EGFR Mutations; NSCLC, Early Stage
- Interventions
- TAS6417; Zipalertinib Matching-placebo
- Arms
- Zipalertinib · Experimental
- Placebo · Placebo comparator
- Enrollment
- 360 (estimated)
- Primary outcomes
- Disease-free Survival (DFS) as Assessed by the Investigator
- Sponsor
- Taiho Oncology, Inc.
- Start
- Dec 22, 2025
- Primary completion
- Oct 1, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT07128199 · updated Oct 13, 2026